Antibiotic-Releasing Polymer May Help Eradicate Joint Implant Infection

In the new approach to treating prosthetic joint infection, developed by Massachusetts General Hospital investigators, the infected prosthesis and affected tissue are removed and the new prosthesis, incorporating an antibody-releasing polymer, is implanted in a single procedure. The antibiotic -- in this example vancomycin -- is released over time to eradicate any bacteria that remain and prevent future infection. Courtesy of Jeremy Vincentius Suhardi, Harris Orthopædics Laboratory, Massachusetts General Hospital  

A team of Massachusetts General Hospital (MGH) investigators has developed an antibiotic-releasing polymer that may greatly simplify the treatment of prosthetic joint infection. In their recent report published in Nature Biomedical Engineering, the researchers describe how implants made from this material successfully eliminated two types of prosthetic infection in animal models.

"Currently, most infections involving total joint replacement prostheses require a two-stage surgery, in which the patient's daily activities are largely compromised for four to six months," says Orhun Muratoglu, PhD, director of the Harris Orthopedics Laboratory in the MGH Department of Orthopedic Surgery, a co-author of the report. "Our finding that polyethylene, the most commonly used weight-bearing surface in total joint surgery, can be made to safely and effectively release antibiotics implies that fully weight-bearing implants made with this material could be used to treat infection in a single procedure, reducing both the inconvenience and the risk of complications for patients."

Delivering antibiotics to an infected prosthetic joint is challenging because of the limited supply of blood to the area. As Muratoglu describes, the standard treatment for prosthetic joint infection in the U.S. -- which affects up to 30,000 people each year -- involves removal of the implant and adjacent infected tissues and placement of a temporary spacer made from antibiotic-releasing bone cement that remains within the joint space for at least six weeks and sometimes for as long as six months. During that time, the patient's movement may be significantly restricted, depending on the involved joint. In a second surgery, a new prosthesis is implanted, using antibiotic-releasing bone cement. But patients still can be at risk for recurrent infection, which may lead to the need for permanent joint fusion or amputation and has a 10-15 percent mortality rate.

Antibiotic-releasing bone cement has several limitations. Its ability to release an effective antibiotic dose may be brief, lasting little more than a week, and increasing the antibiotic content reduces the material's durability. In addition, some antibiotics with desirable qualities cannot be incorporated into a bone cement. For the current study, the research team - including lead author Jeremy Vincentius Suhardi, a Harvard/MIT MD/PhD student, and senior author Ebru Oral, PhD, both of the Harris Lab - designed and developed an antibiotic-releasing polymer that could be incorporated into the implant itself.

Based on mathematical and statistical models, the material they developed contained antibiotic clusters which were irregularly shaped, making them able to release effective drug doses over extended periods of time without compromising the strength of the material. Implants made from this polymer were tested in animal models of prosthetic joint infection produced either by injecting a Staph. aureus-containing solution into the prosthesis or implanting a titanium rod covered with a Staph. Aureus biofilm, a coating of bacteria that is particularly difficult to treat. In both situations, the antibiotic-releasing polymer successfully eliminated the infection, while implantation of a drug-release bone cement spacer was not effective.

"We used two separate infection models because, when patients present with prosthetic joint infection symptoms, it is not clear what proportion of bacteria may be in a biofilm and what are free floating in solution," says Muratoglu. "The ability of our devices to eradicate all bacteria in the joints in both models strongly suggests they would be successful against both types of periprosthetic infection." A professor of Orthopedic Surgery at Harvard Medical School, Muratoglu notes that, in addition to speeding the recovery of patients and reducing the chance of complications, the elimination of a second surgical procedure should reduce overall costs.

He adds that the successful development of devices like these implants relies on an institutional "ecosystem," involving scientists, engineers and surgeons who can identify a problem, form hypotheses and strategies, and develop and test materials to meet the challenges. The team is now working with the Food and Drug Administration and other regulatory agencies to pursue necessary approvals and develop this material into clinical products.

Additional co-authors of the Nature Biomedical Engineering report are David Bichara, MD, Harris Orthopædics Laboratory; Andrew Freiberg, MD, Harry Rubash, MD, and Henrick Malchau, MD, PhD, MGH Department of Orthopædic Surgery; and Sheldon Kwok and Seok-Hyun (Andy) Yun, PhD, MGH Wellman Center for Photomedicine. Support for the study includes National Institutes of Health grants P01-HL120839 and P41-EB015903. A patent application covering the work described in this study has been filed.

Source: Massachusetts General Hospital